10x Genomics (TXG) Payables (2018 - 2026)

10x Genomics has disclosed Payables across 9 years of filings, most recently posting $17.4 million for Q1 2026.

• Payables for Q1 2026 came in at $17.4 million, up 73.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $17.4 million (up 73.07% YoY), and the FY2025 annual result was $12.7 million, down 1.36% from the prior year.
• Payables came in at $17.4 million for Q1 2026 at 10x Genomics, up from $12.7 million in the prior quarter.
• In the past five years, Payables ranged from a high of $29.3 million in Q1 2023 to a low of $10.1 million in Q1 2025.
• The 5-year median for Payables is $19.0 million (2022), against an average of $19.5 million.
• Across the five-year window, Payables plunged 50.2% in 2025 and soared 73.07% in 2026, its largest moves.
• 10x Genomics' Payables stood at $21.6 million in 2022, then fell by 27.14% to $15.7 million in 2023, then declined by 17.98% to $12.9 million in 2024, then retreated by 1.36% to $12.7 million in 2025, then jumped by 36.85% to $17.4 million in 2026.
• The last three Payables figures came in at $17.4 million (Q1 2026), $12.7 million (Q4 2025), and $18.1 million (Q3 2025), per Business Quant data.